AmerisourceBergen elevates Steve Collis to president and COO
The Big Three distributor’s board of directors has appointed Collis, currently president of AmerisourceBergen Drug Corp. (ABDC, the pharma wholesaling arm of the company) to president and chief operating officer of the parent. He will report to R. David Yost, AmerisourceBergen’s CEO, who previously also held the title of president.
Collis is now responsible for all AmerisourceBergen business units, including ABDC, AmerisourceBergen Specialty Group (ABSG), AmerisourceBergen Packaging Group (ABPG) and AmerisourceBergen Consulting Services (ABCS). ABSG and ABCS previously reported to Yost, and ABPG previously reported to Michael DiCandilo, EVP and CFO.
Collis, who has been at AmerisourceBergen for 16 years, has been president of ABSG since 1999; that unit is now a fast-growing, $16-billion part of the company. This month, the company also announced its FY2010 results, with revenue reaching a new record, $78.0 billion, up 8.6%, and gross profit of $2.4 billion, up 12.2%.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
